medigraphic.com

2007, Number S4

<< Back Next >>

Arch Cardiol Mex 2007; 77 (S4)

Antithrombotic regulation by fibrinolytic system

Peña DA, Cruz RD, Pérez MÓ, García TJJ, Arce FM, Vargas AG

Language: Spanish
References: 59
Page: 82-87
PDF size: 116.36 Kb.


ABSTRACT

In this work it is emphasized the presence of the fibrinolítico system in different physiological mechanisms, specially in the antithrombotic regulation of the hemostasis. It is described: the mechanism of activation of plasminogen by their activators as much on the fibrin as in the cells surface; the inhibition of the activators in different metabolic alterations.


REFERENCES

  1. Rosenberg R, Aird W: Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J of Med 1999; 20: 1555-64.

  2. Knowles RG, Moncada S: Nitric oxide as a signal in blood vessels. TIBS 1992; 17: 399-402.

  3. Jin RC, Voetsch B, Loscalzo J: Endogenous mechanisms of inhibition of platelet function. Microcirculation 2005; 12: 247-58.

  4. Hermann M: Cyclooxygenase-2 and nitric oxide. J Cardiovasc Pharmacol 2006; 47 Suppl 1: S21-5.

  5. Aikawa J, Esko JD: Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAc N-deacetylase/ N-sulfotransferase family. J Biol Chem 1999; 274: 2690-5.

  6. Van de Wouwer M, Collen D, Conway EM: Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24: 1374-83.

  7. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.

  8. Bouma BN, Mosnier LO: Thrombin activatable fibrinolysis inhibitor (TAFI)-How does thrombin regulate fibrinolysis? Ann Med 2006; 38(6): 378-88.

  9. Collen D, Lijnen HR: Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004; 2: 541-6.

  10. Wiel E, Vallet B, ten Cate H: The endothelium in intensive care. Crit Care Clin 2005; 21: 403-16.

  11. Neurath H: Proteolytic processing and physiological regulation. TIBS 1989; 14: 268-271.

  12. Wiman B, Hamsten A: The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990; 16: 207-16.

  13. Collen D, Lijnen HR: The fibrinolytic system in man. Crit Rev Oncol Hematol 1986; 4: 249-301.

  14. Anglés-Cano E: Overview on fibrinolysis: plasminogen activation pathway on fibrin and cell surfaces. Chem Phys Lipids 1994; 67: 353-62.

  15. Dobrovolsky AB, Titaeva EV: The fibrinolysis System: regulation of activity and physiology functions of its main components. Biochemistry 2002; 67: 99-108.

  16. Cesarman-Maus G, Hajjar KA: Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.

  17. Werb Z, Mainardi CL, Vater CA, Harris ED: Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role for plasminogen activator. N Engl J Med 1977; 296: 1017-23.

  18. Ho-Tin-Noe B, Rojas G, Vranckx R, Lijnen HR, Angles-Cano E: Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis. FEBS J 2005; 272: 3387-400.

  19. Daci E, Udagawa N, Martin TJ, Bouillon R, Carmeliet G: The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res. 1999; 14: 946-52.

  20. Raikkonen K, Lassila R, Keltikangas-Jarvinen L, Hautanen A: Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler Thromb Vasc Biol 1996; 16: 363-7.

  21. Cho SH, Ryu CH, Oh CK: Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med 2004; 229: 138-46.

  22. Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, et al: Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 2003; 17: 1904-6.

  23. Van Ness K, Chobaz-Peclat V, Castellucci M, So A, Busso N: Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis. Rheumatology (Oxford) 2002; 41(2): 136-41.

  24. Lijnen HR: Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.

  25. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996; 271: 10079-86.

  26. Nakagami Y, Abe K, Nishiyama N, Matsuki N: Laminin degradation by plasmin regulates long-term potentiation. J Neurosci 2000; 20: 2003-10.

  27. Kost C, Benner K, Stockmann A, Linder D, Preissner KT: Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996; 236: 682-8.

  28. Lijnen HR: Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2004; 33: 275-81.

  29. Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR: Proteolytic processing of human coagulation factor IX by plasmin. Blood 2000; 95: 943-51.

  30. Schatteman KA, Goossens FJ, Scharpe SS, Hendriks DF: Proteolytic activation of purified human procarboxypeptidase. U Clin Chim Acta 2000; 292: 25-40.

  31. Wallace EM, Perkins SJ, Sim RB, Willis AC, Feighery C, Jackson J: Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol Med 1997; 3: 385-96.

  32. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 1989; 109: 309-15.

  33. Campbell PG, Novak JF, Yanosick TB, McMaster JH: Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 1992; 130: 1401-12.

  34. Hervio LS, Coombs GS, Bergstrom RC, Trivedi K, Corey DR, Madison EL: Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. Chem Biol 2000; 7: 443-53.

  35. Wang N, Zhang L, Miles L, Hoover-Plow J: Plasminogen regulates pro-opiomelanocortin processing. J Thromb Haemost. 2004; 2: 785-96.

  36. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.

  37. Gveric D, Herrera BM, Cuzner ML: tPA receptors and the fibrinolytic response in multiple sclerosis lesions. Am J Pathol 2005; 166: 1143-51.

  38. Tsutsumi S, Saito T, Sakata T, Mlyata T, Ichinose A: Genetic diagnosis of dysplasminogenemia: detection of an Ala601-Thr mutation in 118 out of 125 families and identification of a new Asp676-Asn mutation. Thromb Haemost. 1996; 76: 135-8.

  39. Kwaan HC, Nabhan C: Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin North Am 2003; 17: 103-14.

  40. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.

  41. Crowther MA, Roberts J, Roberts R, Johnston M, Stevens P, Skingley P, et al: Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001; 85: 390-4.

  42. Prins MH, Hirsh J: A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151: 1721-31.

  43. Prins MH, Hirsh J: A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122: 545-51.

  44. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EK: A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991; 77: 528-32.

  45. Agren A, Wiman B, Stiller V, Lindmarker P, Sten-Linder M, Carlsson A, et al: Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006; 4: 201-8.

  46. Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.

  47. Pannacciulli N, De Mitrio V, Marino R, Giorgino R, De Pergola G. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 2002; 10: 717-25.

  48. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM: Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753-9.

  49. Garcia-Touchard A, Henry TD, Sangiorgi G, Spagnoli LG, Mauriello A, Conover C, Schwartz RS: Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 2005; 25: 1119-27.

  50. Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z: Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005; 115: 879-87.

  51. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.

  52. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.

  53. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U: Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 2019-23.

  54. Zureik M, Robert L, Courbon D, Touboul PJ, Bizbiz L, Ducimetiere P: Serum elastase activity, serum elastase inhibitors, and occurrence of carotid atherosclerotic plaques: the etude sur le vieillissement arteriel (EVA) study. Circulation 2002; 105: 2638-45.

  55. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potencial role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.

  56. Anglés-Cano E, de la Peña A, Loyau S: Inhibition of fibrinolysis by lipoprotein (a). Ann NY Acad of Sci 2001; 936: 261-75.

  57. de la Peña-Díaz A, Cardoso-Saldaña G, Zamora-González J, Barinagarrementeria F, Loyau S, Izaguirre R, Anglés-Cano E: Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases. Eur J of Clin Invest 2003; 33: 99-105.

  58. de la Peña-Díaz A, Izaguirre-Avila R, Anglés-Cano E: Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res 2000; 31: 353-359.

  59. Emanuele E, Peros E, Tomaino C, Feudatari E, Bernardi L, Binetti G, et al: Relation of apolipoprotein(a) size to alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 2004; 18: 189-96.




2020     |     www.medigraphic.com